AL
CTMX icon

Airain Ltd’s CytomX Therapeutics CTMX Stock Holding History

Airain Ltd’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$315K Buy
+20,292
New +$306K 0.01% 650

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Airain Ltd's CTMX Position: Q2 2017 in Review

Airain Ltd opened a new position in CytomX Therapeutics (CTMX) in Q2 2017: 20,292 shares worth $315K. The stake represents 0.01% of the portfolio and ranks #650 among its holdings.

90 funds tracked by Wall St. Rank hold CTMX as of Q2 2017.

  • Airain Ltd held 20,292 shares of CytomX Therapeutics worth $315K as of Q2 2017.
  • CytomX Therapeutics was a new Airain Ltd position in Q2 2017.
  • CytomX Therapeutics made up 0.01% of Airain Ltd's portfolio in Q2 2017, its #650 holding.
  • 90 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.